Thermogenesis agreement for cord blood systems with umbilical cord Stem Cells Company

Thermogenesis has recently announced agreement with the Beike, a Chinese stem cell company. Thermogenesis is among the top most supplier of the most innovative products and services dealing in storage of adult stem cells. Beike is the leading stem cell banking and regeneration company of China. 

Thermogenesis Corp. -

Thermogenesis is the leader in developing and manufacturing of the blood processing systems and disposable products. Several systems it offers are- 

• BioArchive system – It is a cryogenic device which is used for baby cord blood banking in more than thirty countries.
• AXP Autoexpress – They are those automated devices that include AXP and MXP and also blood processing for harvesting stem cells. AXP is used for cord blood processing

In addition to these, others are CryoSeal FS system and Res-Q systems. 

Bekie Biotechnology Co. Ltd.-

Bekie has its headquarters in Shenzhen that is in China with its offices in several major cities of the country. The company is one of the most reputed biotechnology companies in stem cell therapies and cell banking. The scientists of the firm are highly dedicated to develop and commercialize stem cells therapies since the year 1999. However, banking operations were started in 2008. At present, the company produces stem cells obtained from bone marrow and cord blood tissue and also from private cord blood banking. It has three cord blood processing and storage units and five stem cells banks. There are eighteen laboratories for cord blood collection and two research laboratories for stem cells.   

With the help of this agreement, Thermogenesis will supply stocks for the fiscal year 2011 of its AXP and BioArchive systems. As per CEO of Thermogenesis, the company is pleased with its agreement with Beike which is known to be a regenerative leader in the Chinese economy. The partnership further has opened new doors for the company to expand its share in the Chinese market. The company would also step into prospective sector of umbilical cord storage with advanced stem cell therapies. With the collaboration of the two companies, both will develop advanced technologies and maximize the automation of the process. 

According to Beike’s CEO, AXP and BioArchive systems are the most important perspectives of the company’s strategy to become technology and quality king. It will become the first bank in China to have recognition for cord blood processing and storage.  Compare cord blood banks all around the universe and one will find that Beike is among the topmost market players. This collaboration will be highly beneficial for both companies.

Leukemia and lymphoma baby boomers have new hope

A new ray of hope has been shown by doctors of Loyola University Hospital. Patients who are above sixty and suffering from chronic diseases like leukemia and lymphoma are considered ineligible for the umbilical cord blood stem cells transplant. However, according to Loyola hospital doctors, it can offer treatment to patients even in their sixties or early seventies. The reason quoted by the director of Loyola Cancer Center was that most of the aged people today are much concerned about their health. They do exercises, run marathons and therefore have developed the ability to live for a longer time period.

This is the reason that it is safe for them to receive a transplant of stem cells just like teenagers. The median age of patients when they suffer from blood cancer is 65 to 68. Those who have this cancer and undergo conventional surgical methods possess less than five percent survival rate for five years. However, in Loyola six out of seven patients who have undergone this cord blood stem cells transplants are showing better performance than expected. A fact that becomes integral to know at this point is the stem cell transplantation is very risky and an exhausting treatment. 

The patient is given chemotherapy and also radiation for the destruction of cancer cells.  This also damages the cells of immune system of the patient. For that, sufferer is induced with donor stem cells that further develop into immune system cells.  Beside these the body might also develop several infections until immune system gets developed completely.  Once immune system gets developed under some conditions, it might attack own body. This is called graft vs. host disease. As a result, several drugs are provided that further boost the risks of many infections. Donor cells are taken from bone marrow or from umbilical cord storage.

Cord blood transplant is considered safe on the baby boomers than bone marrow transplant. Only ten percent of people with cord transplant develop graft vs. host disease as compared to fifty percent with bone marrow. However, a small quantity of stem cells is derived form cord blood which further increases the time limit to develop immune system. The center is involved in a medical trial in which cord blood is sent to laboratory to double the stem cell count. Loyola has cured more than 3000 patients till now and is one of the largest donor programs in the whole world. It has performed above ninety transplants. Moreover, it is the center’s experience that decides the success rate of the transplant.